Novartis India open offer sees only 10 shares tendered, 0.00% of target

What Novartis India announced

Novartis India Ltd filed an update on its open offer on 19 June 2026. The offer, managed by Axis Capital Ltd, seeks to acquire up to 6,419,608 fully paid‑up equity shares of face value ₹5 each from public shareholders. This represents 26 % of the company’s voting share capital. The filing disclosed the number of shares actually tendered up to the reporting date.

Structure of the open offer

The open offer is being made by three strategic investors acting in concert:

• WaveRise Investments Limited (Acquirer 1)
• ChrysCapital Fund X, the first scheme of ChrysCapital Trust I (Acquirer 2)
• Two Infinity Partners (Acquirer 3)

Both Acquirer 1 and Acquirer 2 are supported by persons acting in concert (PACs) – ChrysCapital X, LLC (PAC 1) and OceanEdge Investments Limited (PAC 2). The offer is governed by the SEBI (Substantial Acquisition of Shares and Take‑overs) Regulations and the Letter of Offer dated 1 June 2026.

Tender status as of 19 June 2026

The manager to the open offer, Axis Capital Ltd, reported the following tender figures:

• Dematerialised shares: Nil (0 % of the offer size) have been deposited in the designated escrow demat account with Ventura Securities Ltd.
• Physical shares: 10 shares (0.00 % of the offer size) have been received by the registrar in physical form.

Both figures are provisional and subject to verification of documentation. The filing stresses that the number of validly tendered shares may differ from the number ultimately accepted by the acquirers.

Key facts at a glance

Why this matters for investors

The open offer was launched to enable the acquirers to secure a strategic 26 % stake in Novartis India. The extremely low tender response – essentially no demat participation and only ten physical shares – indicates that public shareholders have not shown interest in selling at the terms offered. For existing shareholders, the immediate impact is limited: there is no dilution from accepted shares because none have been validated yet. However, the lack of participation could signal market perception of the offer price, the acquirers’ credibility, or broader sentiment toward the pharmaceutical sector. The filing also reminds investors that any shares eventually accepted will be subject to SEBI’s validation process, which could affect the final ownership structure.

Conclusion

Novartis India’s open offer, targeting 6.42 million shares, has attracted virtually no interest from public shareholders as of 19 June 2026, with only ten physical shares tendered. The acquirers and their PACs remain poised to acquire the shares, but the final outcome depends on subsequent validation and acceptance under SEBI regulations. Investors should monitor future disclosures for any change in tender levels or acceptance decisions.

"NIL Equity Shares, constituting NIL% of the Offer Size, have been tendered till June 19, 2026 in the Open Offer Escrow Demat Account." – Axis Capital Ltd, 19 June 2026